A Study to Assess the Safety and Pharmacokinetics of AD-104-A

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-104-A

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Addpharma Inc.

Criteria

Inclusion Criteria:

For all subjects

• Adults aged 19 years and older

• Body mass index(BMI) of 18 to 30 kg/m2

• Voluntarily given written informed consent

For renal Impairment subjects

• 30 ≤ eGFR < 90 mL/min/1.73m^2

For healthy subjects

• eGFR ≥ 90 mL/min/1.73m^2

Exclusion Criteria:

• Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration

• Other exclusions applied